|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
EphA1 is a possible target of molecular targeted therapy of gastric cancer.
|
25391265 |
2015 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
EphA1 is a possible target of molecular targeted therapy of gastric cancer.
|
25391265 |
2015 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptor tyrosine kinases control cell-cell interactions during normal and oncogenic development, and are implicated in a range of processes including angiogenesis, stem cell maintenance and metastasis.
|
25391995 |
2014 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eph receptor tyrosine kinases and the corresponding ephrin ligands play a pivotal role in the glioma development and progression.
|
25418012 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptor tyrosine kinases are considered candidate therapeutic targets in cancer, but they can exert opposing effects on cell growth.
|
26130649 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptor tyrosine kinases are considered candidate therapeutic targets in cancer, but they can exert opposing effects on cell growth.
|
26130649 |
2015 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors, the largest subfamily of transmembrane tyrosine kinase receptors, have been increasingly implicated in various physiologic and pathologic processes, and the roles of the Eph family members during tumorigenesis have recently attracted growing attentions.
|
27986811 |
2017 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptors comprise the largest group of the receptor tyrosine kinase (RTK) family, and Eph receptors interacting with their ligand ephrins play an important role in development and tumorigenesis.
|
28453458 |
2017 |
|
Malignant neoplasm of ovary
|
0.030 |
Biomarker
|
disease |
BEFREE |
EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC.
|
28739735 |
2017 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC.
|
28739735 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
EPHA1 may promote the aggression of some OC cells and, thus, be considered a potential therapeutic target for the treatment of malignant OC.
|
28739735 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Eph receptor tyrosine kinases and their ephrin ligands are overexpressed in various human cancers, including colorectal malignancies, suggesting important roles in many aspects of cancer development and progression as well as in cellular repulsive responses.
|
28931592 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Eph receptor tyrosine kinases and their ephrin ligands are overexpressed in various human cancers, including colorectal malignancies, suggesting important roles in many aspects of cancer development and progression as well as in cellular repulsive responses.
|
28931592 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptors play critical roles in embryonic development and human diseases including cancer.
|
29392452 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptors play critical roles in embryonic development and human diseases including cancer.
|
29392452 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EphA1 protein was detected in ovarian cancer cell lines and in a set of formalin‑fixed tissues, including normal fallopian tube, ovarian benign serous cystadenoma, borderline serous tumors and serous carcinoma.
|
29393455 |
2018 |
|
Cystadenocarcinoma, Serous
|
0.010 |
Biomarker
|
disease |
BEFREE |
EphA1 protein was detected in ovarian cancer cell lines and in a set of formalin‑fixed tissues, including normal fallopian tube, ovarian benign serous cystadenoma, borderline serous tumors and serous carcinoma.
|
29393455 |
2018 |
|
Cystadenoma, Serous
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
EphA1 expression was positively detected in all normal fallopian tubes (10/10, 100%) and ovarian benign serous cystadenomas (12/12, 100%) as well as in some borderline serous tumors (9/15, 60%) and ovarian serous carcinomas (33/76, 43.42%).
|
29393455 |
2018 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
EphA1 expression was positively detected in all normal fallopian tubes (10/10, 100%) and ovarian benign serous cystadenomas (12/12, 100%) as well as in some borderline serous tumors (9/15, 60%) and ovarian serous carcinomas (33/76, 43.42%).
|
29393455 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph receptor functions contribute to tumor development, modulating cell-cell adhesion, invasion, neo-angiogenesis, tumor growth and metastasis.
|
29653204 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptor functions contribute to tumor development, modulating cell-cell adhesion, invasion, neo-angiogenesis, tumor growth and metastasis.
|
29653204 |
2018 |
|
Tumor Angiogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Eph receptor functions contribute to tumor development, modulating cell-cell adhesion, invasion, neo-angiogenesis, tumor growth and metastasis.
|
29653204 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Eph receptor functions contribute to tumor development, modulating cell-cell adhesion, invasion, neo-angiogenesis, tumor growth and metastasis.
|
29653204 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph proteins have emerged as critical drivers affecting tumor growth and progression in human malignancies.
|
29970482 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eph proteins have emerged as critical drivers affecting tumor growth and progression in human malignancies.
|
29970482 |
2018 |